Phase 3 Muscular Atrophy Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Spinal Muscular Atrophy
Biogen90 enrolled1 locationNCT07444476
Recruiting
Phase 3
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals175 enrolled32 locationsNCT05335876
Recruiting
Phase 3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Muscular Atrophy, Spinal
Biogen30 enrolled2 locationsNCT07221669
Recruiting
Phase 3
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
Spinal Muscular Atrophy (SMA)
Lantu Biopharma15 enrolled1 locationNCT07265232
Recruiting
Phase 3
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
SMA - Spinal Muscular Atrophy
GeneCradle Inc50 enrolled7 locationsNCT06971094
Recruiting
Phase 2Phase 3
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Spinal and Bulbar Muscular Atrophy
Masahisa Katsuno68 enrolled5 locationsNCT06862596